| Integrative clinical genomics of advanced prostate cancer D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ... Cell 161 (5), 1215-1228, 2015 | 3622 | 2015 |
| MicroRNA profiling: approaches and considerations CC Pritchard, HH Cheng, M Tewari Nature Reviews Genetics 13 (5), 358-369, 2012 | 1864 | 2012 |
| Inherited DNA-repair gene mutations in men with metastatic prostate cancer CC Pritchard, J Mateo, MF Walsh, N De Sarkar, W Abida, H Beltran, ... New England Journal of Medicine 375 (5), 443-453, 2016 | 1565 | 2016 |
| Quantitative and stoichiometric analysis of the microRNA content of exosomes JR Chevillet, Q Kang, IK Ruf, HA Briggs, LN Vojtech, SM Hughes, ... Proceedings of the National Academy of Sciences 111 (41), 14888-14893, 2014 | 1089 | 2014 |
| Plasma processing conditions substantially influence circulating microRNA biomarker levels HH Cheng, HS Yi, Y Kim, EM Kroh, JW Chien, KD Eaton, MT Goodman, ... PloS one 8 (6), e64795, 2013 | 355 | 2013 |
| NCCN guidelines insights: Prostate cancer, version 1.2021: Featured updates to the NCCN guidelines E Schaeffer, S Srinivas, ES Antonarakis, AJ Armstrong, JE Bekelman, ... Journal of the National Comprehensive Cancer Network 19 (2), 134-143, 2021 | 341 | 2021 |
| Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer HH Cheng, CC Pritchard, T Boyd, PS Nelson, B Montgomery European urology 69 (6), 992-995, 2016 | 287 | 2016 |
| Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer MP Labrecque, IM Coleman, LG Brown, LD True, L Kollath, B Lakely, ... The Journal of clinical investigation 129 (10), 4492-4505, 2019 | 271 | 2019 |
| Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019 VN Giri, KE Knudsen, WK Kelly, HH Cheng, KA Cooney, MS Cookson, ... Journal of Clinical Oncology 38 (24), 2798-2811, 2020 | 227 | 2020 |
| Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia HH Cheng, PS Mitchell, EM Kroh, AE Dowell, L Chéry, J Siddiqui, ... PloS one 8 (7), e69239, 2013 | 195 | 2013 |
| NCCN guidelines® insights: prostate cancer, version 1.2023: featured updates to the NCCN guidelines EM Schaeffer, S Srinivas, N Adra, Y An, D Barocas, R Bitting, A Bryce, ... Journal of the National Comprehensive Cancer Network 20 (12), 1288-1298, 2022 | 146 | 2022 |
| Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations CH Marshall, AO Sokolova, AL McNatty, HH Cheng, MA Eisenberger, ... European urology 76 (4), 452-458, 2019 | 140 | 2019 |
| Germline and somatic mutations in prostate cancer for the clinician HH Cheng, AO Sokolova, EM Schaeffer, EJ Small, CS Higano Journal of the National Comprehensive Cancer Network 17 (5), 515-521, 2019 | 125 | 2019 |
| A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer MT Schweizer, K Haugk, JS McKiernan, R Gulati, HH Cheng, JL Maes, ... PloS one 13 (6), e0198389, 2018 | 123 | 2018 |
| Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, YY Evan, ... The Lancet Oncology 23 (3), 362-373, 2022 | 122 | 2022 |
| Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH trial (EAY131) subprotocol W YK Chae, F Hong, C Vaklavas, HH Cheng, P Hammerman, EP Mitchell, ... Journal of Clinical Oncology 38 (21), 2407, 2020 | 120 | 2020 |
| Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study J Mateo, HH Cheng, H Beltran, D Dolling, W Xu, CC Pritchard, H Mossop, ... European urology 73 (5), 687-693, 2018 | 118 | 2018 |
| Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference K Jensen, EQ Konnick, MT Schweizer, AO Sokolova, P Grivas, HH Cheng, ... JAMA oncology 7 (1), 107-110, 2021 | 105 | 2021 |
| Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel HH Cheng, R Gulati, A Azad, R Nadal, P Twardowski, UN Vaishampayan, ... Prostate cancer and prostatic diseases 18 (2), 122-127, 2015 | 100 | 2015 |
| Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations MT Schweizer, ES Antonarakis, TA Bismar, LB Guedes, HH Cheng, ... JCO precision oncology 3, 1-9, 2019 | 86 | 2019 |
